Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model
Identifieur interne : 002098 ( Main/Exploration ); précédent : 002097; suivant : 002099Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model
Auteurs : Paul A. Rota [États-Unis] ; Barun K. De [États-Unis] ; Michael W. Shaw [États-Unis] ; Renee A. Black [États-Unis] ; William C. Gamble [États-Unis] ; Alan P. Kendal [États-Unis]Source :
- Virus Research [ 0168-1702 ] ; 1990.
English descriptors
- Teeft :
- Amino acid sequences, Antibody response, Antigen levels, Assay, Attenuated vaccines, Cell line, Challenge experiments, Control animals, Control mice, Days postchallenge, Days postinfection, Days postvaccination, Detectable levels, Detectable serum neutralizing antibodies, Disease control, Full protection, Hemagglutinin, Human influenza, Immune responses, Influenza, Influenza hemagglutinin, Influenza immunization, Influenza infection, Influenza vaccination, Influenza vaccines, Influenza virus, Influenza virus type, Influenza virus vaccines, Influenza viruses, Intranasal, Intranasal route, Intranasally, Intraperitoneal, Intraperitoneal route, Intraperitoneal vaccination, Kendal, Local immunity, Lung homogenates, Mice vaccinated, Monoclonal antibodies, Months postvaccination, Mouse, Neutralizing, Neutralizing antibodies, Neutralizing antibody, Peak antigen levels, Peak levels, Protective immunity, Recombinant, Recombinant vaccinia virus, Recombinant vaccinia virus vaccines, Recombinant vaccinia viruses, Rota, Sequence changes, Serum antibody, Serum samples, Vaccinated, Vaccinated mice, Vaccination, Vaccine, Vaccinia, Vaccinia virus, Vaccinia virus expression vectors, Viral, Viral pneumonia, Virus, Virus vaccines, Yellow fever virus.
Abstract
Abstract: The protective efficacy of influenza hemagglutinin expressed from recombinant vaccinia virus was compared with that induced by inactivated or infectious influenza vaccines. Intraperitoneal and intranasal routes of vaccination were compared. All the vaccines except the intranasally administered, inactivated vaccine induced detectable levels of neutralizing and hemagglutination-inhibiting antibodies in the serum of mice at 28 days postvaccination. Immunization with any of the intranasally administered vaccines reduced the amount of influenza virus nucleoprotein antigen in lungs after challenge with a homologous, mouse-adapted strain of influenza virus. Intraperitoneally administered vaccines failed to provide such protection. These results indicated that the route of vaccine administration may be the most critical factor for inducing protective immunity. The results also showed that in this mouse model a recombinant DNA-based vaccine could provide protection equivalent to that provided by conventional attenuated and inactivated influenza vaccines.
Url:
DOI: 10.1016/0168-1702(90)90045-D
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000531
- to stream Istex, to step Curation: 000531
- to stream Istex, to step Checkpoint: 000E28
- to stream Main, to step Merge: 002199
- to stream Main, to step Curation: 002098
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model</title><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name></author><author><name sortKey="De, Barun K" sort="De, Barun K" uniqKey="De B" first="Barun K." last="De">Barun K. De</name></author><author><name sortKey="Shaw, Michael W" sort="Shaw, Michael W" uniqKey="Shaw M" first="Michael W." last="Shaw">Michael W. Shaw</name></author><author><name sortKey="Black, Renee A" sort="Black, Renee A" uniqKey="Black R" first="Renee A." last="Black">Renee A. Black</name></author><author><name sortKey="Gamble, William C" sort="Gamble, William C" uniqKey="Gamble W" first="William C." last="Gamble">William C. Gamble</name></author><author><name sortKey="Kendal, Alan P" sort="Kendal, Alan P" uniqKey="Kendal A" first="Alan P." last="Kendal">Alan P. Kendal</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F7790536431FD534E47C9A95FCDDA164F4B7297</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/0168-1702(90)90045-D</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-XPHD0JNV-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000531</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000531</idno><idno type="wicri:Area/Istex/Curation">000531</idno><idno type="wicri:Area/Istex/Checkpoint">000E28</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E28</idno><idno type="wicri:doubleKey">0168-1702:1990:Rota P:comparison:of:inactivated</idno><idno type="wicri:Area/Main/Merge">002199</idno><idno type="wicri:Area/Main/Curation">002098</idno><idno type="wicri:Area/Main/Exploration">002098</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model</title><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="De, Barun K" sort="De, Barun K" uniqKey="De B" first="Barun K." last="De">Barun K. De</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Shaw, Michael W" sort="Shaw, Michael W" uniqKey="Shaw M" first="Michael W." last="Shaw">Michael W. Shaw</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Black, Renee A" sort="Black, Renee A" uniqKey="Black R" first="Renee A." last="Black">Renee A. Black</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Gamble, William C" sort="Gamble, William C" uniqKey="Gamble W" first="William C." last="Gamble">William C. Gamble</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Kendal, Alan P" sort="Kendal, Alan P" uniqKey="Kendal A" first="Alan P." last="Kendal">Alan P. Kendal</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, Atlanta, GA 30333</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Virus Research</title><title level="j" type="abbrev">VIRUS</title><idno type="ISSN">0168-1702</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="83">83</biblScope><biblScope unit="page" to="93">93</biblScope></imprint><idno type="ISSN">0168-1702</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0168-1702</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amino acid sequences</term><term>Antibody response</term><term>Antigen levels</term><term>Assay</term><term>Attenuated vaccines</term><term>Cell line</term><term>Challenge experiments</term><term>Control animals</term><term>Control mice</term><term>Days postchallenge</term><term>Days postinfection</term><term>Days postvaccination</term><term>Detectable levels</term><term>Detectable serum neutralizing antibodies</term><term>Disease control</term><term>Full protection</term><term>Hemagglutinin</term><term>Human influenza</term><term>Immune responses</term><term>Influenza</term><term>Influenza hemagglutinin</term><term>Influenza immunization</term><term>Influenza infection</term><term>Influenza vaccination</term><term>Influenza vaccines</term><term>Influenza virus</term><term>Influenza virus type</term><term>Influenza virus vaccines</term><term>Influenza viruses</term><term>Intranasal</term><term>Intranasal route</term><term>Intranasally</term><term>Intraperitoneal</term><term>Intraperitoneal route</term><term>Intraperitoneal vaccination</term><term>Kendal</term><term>Local immunity</term><term>Lung homogenates</term><term>Mice vaccinated</term><term>Monoclonal antibodies</term><term>Months postvaccination</term><term>Mouse</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Neutralizing antibody</term><term>Peak antigen levels</term><term>Peak levels</term><term>Protective immunity</term><term>Recombinant</term><term>Recombinant vaccinia virus</term><term>Recombinant vaccinia virus vaccines</term><term>Recombinant vaccinia viruses</term><term>Rota</term><term>Sequence changes</term><term>Serum antibody</term><term>Serum samples</term><term>Vaccinated</term><term>Vaccinated mice</term><term>Vaccination</term><term>Vaccine</term><term>Vaccinia</term><term>Vaccinia virus</term><term>Vaccinia virus expression vectors</term><term>Viral</term><term>Viral pneumonia</term><term>Virus</term><term>Virus vaccines</term><term>Yellow fever virus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The protective efficacy of influenza hemagglutinin expressed from recombinant vaccinia virus was compared with that induced by inactivated or infectious influenza vaccines. Intraperitoneal and intranasal routes of vaccination were compared. All the vaccines except the intranasally administered, inactivated vaccine induced detectable levels of neutralizing and hemagglutination-inhibiting antibodies in the serum of mice at 28 days postvaccination. Immunization with any of the intranasally administered vaccines reduced the amount of influenza virus nucleoprotein antigen in lungs after challenge with a homologous, mouse-adapted strain of influenza virus. Intraperitoneally administered vaccines failed to provide such protection. These results indicated that the route of vaccine administration may be the most critical factor for inducing protective immunity. The results also showed that in this mouse model a recombinant DNA-based vaccine could provide protection equivalent to that provided by conventional attenuated and inactivated influenza vaccines.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name></region><name sortKey="Black, Renee A" sort="Black, Renee A" uniqKey="Black R" first="Renee A." last="Black">Renee A. Black</name><name sortKey="De, Barun K" sort="De, Barun K" uniqKey="De B" first="Barun K." last="De">Barun K. De</name><name sortKey="Gamble, William C" sort="Gamble, William C" uniqKey="Gamble W" first="William C." last="Gamble">William C. Gamble</name><name sortKey="Kendal, Alan P" sort="Kendal, Alan P" uniqKey="Kendal A" first="Alan P." last="Kendal">Alan P. Kendal</name><name sortKey="Shaw, Michael W" sort="Shaw, Michael W" uniqKey="Shaw M" first="Michael W." last="Shaw">Michael W. Shaw</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002098 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002098 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4F7790536431FD534E47C9A95FCDDA164F4B7297
|texte= Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model
}}
| This area was generated with Dilib version V0.6.33. |  |